HealthDay News — An experimental vaccine against COVID-19 appears to be safe and to trigger an immune response, according to results of the first human clinical trial of a COVID-19 vaccine.

The findings from the early-stage trial that started in March included eight healthy people who each received two doses of the vaccine, The New York Times reported.

The volunteers made antibodies that were able to stop COVID-19 from replicating, and the levels of the antibodies were similar to those in people who have recovered after contracting the virus, according to vaccine maker Moderna.

The company said the next phase of the testing will involve 600 people and is scheduled to begin soon, but U.S. officials have cautioned that it could take a year to 18 months to produce a vaccine that would be widely available, The Times reported.


Continue Reading

The New York Times Article

Related Articles